197 related articles for article (PubMed ID: 10471530)
21. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma.
Cohen S; Haimovich J; Hollander N
J Immunol; 2009 Feb; 182(3):1667-73. PubMed ID: 19155516
[TBL] [Abstract][Full Text] [Related]
22. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
23. [Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].
Yin XR; Zhang M; Luo YY; Lin X; He PC; Chen LM; Cai RB; Guo GL
Ai Zheng; 2005 Jun; 24(6):657-62. PubMed ID: 15946473
[TBL] [Abstract][Full Text] [Related]
24. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Wen YJ; Barlogie B; Yi Q
Blood; 2001 Mar; 97(6):1750-5. PubMed ID: 11238117
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
Hájek R; Butch AW
Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
[TBL] [Abstract][Full Text] [Related]
26. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
27. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells.
Dabadghao S; Bergenbrant S; Anton D; He W; Holm G; Yi Q
Br J Haematol; 1998 Mar; 100(4):647-54. PubMed ID: 9531329
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.
Wang S; Hong S; Wezeman M; Qian J; Yang J; Yi Q
Front Biosci; 2007 May; 12():3566-75. PubMed ID: 17485322
[TBL] [Abstract][Full Text] [Related]
29. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
30. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.
Büchler T; Hajek R
Med Oncol; 2002; 19(4):213-8. PubMed ID: 12512914
[TBL] [Abstract][Full Text] [Related]
32. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma.
Cull G; Durrant L; Stainer C; Haynes A; Russell N
Br J Haematol; 1999 Dec; 107(3):648-55. PubMed ID: 10583271
[TBL] [Abstract][Full Text] [Related]
33. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
34. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
Hong S; Qian J; Li H; Yang J; Lu Y; Zheng Y; Yi Q
Cancer Immunol Immunother; 2012 Apr; 61(4):561-71. PubMed ID: 22002243
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R
Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700
[TBL] [Abstract][Full Text] [Related]
36. In-vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma.
Wen YJ; Lim SH
Br J Haematol; 1998 Dec; 103(3):663-8. PubMed ID: 9858214
[TBL] [Abstract][Full Text] [Related]
37. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC).
Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Ann Oncol; 2008 Jun; 19(6):1172-9. PubMed ID: 18272909
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
[TBL] [Abstract][Full Text] [Related]
39. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
Rosenblatt J; Glotzbecker B; Mills H; Vasir B; Tzachanis D; Levine JD; Joyce RM; Wellenstein K; Keefe W; Schickler M; Rotem-Yehudar R; Kufe D; Avigan D
J Immunother; 2011 Jun; 34(5):409-18. PubMed ID: 21577144
[TBL] [Abstract][Full Text] [Related]
40. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
